Brooke was only three years old when she first learned about desmoid tumors. “My mother had six or seven,” she recalls.

Achieved $49.3 million in OGSIVEO® (nirogacestat) net product revenue in the third quarter – – Long-term follow-up data from ...

Brooke was only three years old when she first learned about desmoid tumors. “My mother had six or seven,” she recalls. Brooke’s mother also had 28 surgeries related to her desmoid tumors ...

"In the third quarter, we continued to see robust growth in the U.S. launch of OGSIVEO for adults with desmoid tumors. As we approach nearly one full year on market, we are very encouraged by the ...

Evercore ISI analyst Cory Kasimov initiated coverage of SpringWorks Therapeutics (SWTX) with an Outperform rating and $60 price target ...

In addition to a portfolio of discovery-stage ADCs, our pipeline includes AL102, a gamma secretase inhibitor which is currently in a Phase 3 trial for treatment of desmoid tumors, as well as IM ...

SpringWorks to present long-term efficacy and safety data from phase 3 DeFi trial of Ogsiveo in adults with desmoid tumours at CTOS 2024 meeting ...

Achieved $49.3 million in OGSIVEO® (nirogacestat) net product revenue in the third quarter - - Long-term follow-up data from the Phase 3 DeFi trial of nirogacestat in adults with desmoid tumors highli ...